Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.

In the case of cancer chemotherapy for hepatocellular carcinoma, 5-fluorouracil (5-FU) is used widely, and has typically been given by intrahepatic arterial (i.a.) infusion to increase treatment efficacy and to reduce systemic toxicity.

Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats.

Objectives: In cancer chemotherapy for hepatocellular carcinoma, 5-fluorouracil is widely used and has typically been given by intrahepatic arterial (i.a.) infusion to increase treatment efficacy and reduce systemic toxicity.